XML 64 R51.htm IDEA: XBRL DOCUMENT v3.20.2
License agreements - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 128 Months Ended
Jun. 30, 2020
May 31, 2020
Dec. 31, 2017
Apr. 30, 2016
Sep. 30, 2014
Jan. 31, 2010
Dec. 31, 2009
Nov. 30, 2009
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Dec. 31, 2019
License agreements                            
Revenues                 $ 688,043 $ 529,932 $ 1,256,550 $ 1,027,789    
Minimum                            
License agreements                            
Royalty payments on future global net sales (as a percent)     15.00%                      
JAKAFI                            
License agreements                            
Revenues                 473,706 409,506 933,185 785,117    
Novartis                            
License agreements                            
Upfront and immediate milestone payment to be received under license agreement               $ 210,000            
Upfront payment received under license agreement             $ 150,000              
Immediate milestone payment received under license agreement           $ 60,000                
Revenues                 90,000 0 90,000 0    
Royalties payable $ 70,700               70,700   70,700   $ 70,700 $ 50,200
Reimbursable costs included in accounts receivable 100               100   100   100 $ 400
Research and development expenses reimbursed                 0 400 300 1,000    
Novartis | Pre-specified Events | Maximum                            
License agreements                            
Upfront and immediate milestone payment to be received under license agreement               1,200,000            
Novartis | Development Milestones                            
License agreements                            
Amount recognized and received for the achievement of a predefined milestone                         157,000  
Novartis | Development Milestones | Maximum                            
License agreements                            
Upfront and immediate milestone payment to be received under license agreement               174,000            
Novartis | Regulatory Milestones                            
License agreements                            
Amount recognized and received for the achievement of a predefined milestone                         280,000  
Novartis | Regulatory Milestones | Maximum                            
License agreements                            
Upfront and immediate milestone payment to be received under license agreement               495,000            
Novartis | Sales and Commercial Milestones                            
License agreements                            
Amount recognized and received for the achievement of a predefined milestone                         $ 120,000  
Novartis | Sales and Commercial Milestones | Maximum                            
License agreements                            
Upfront and immediate milestone payment to be received under license agreement               $ 500,000            
Novartis | TABRECTA                            
License agreements                            
Revenues                 700   700      
Novartis | TABRECTA | Development Milestones                            
License agreements                            
Amount recognized and received for the achievement of a predefined milestone   $ 25,000                        
Novartis | TABRECTA | Regulatory Milestones                            
License agreements                            
Amount recognized and received for the achievement of a predefined milestone   $ 45,000                        
Novartis | TABRECTA | Regulatory Milestones | JAPAN                            
License agreements                            
Amount recognized and received for the achievement of a predefined milestone $ 20,000                          
Novartis | GVHD | Development and Regulatory Milestones | Maximum                            
License agreements                            
Upfront and immediate milestone payment to be received under license agreement       $ 75,000                    
Novartis | JAKAFI | U.S.                            
License agreements                            
Royalties payable on net sales                 23,200 20,100 40,700 33,500    
Novartis | JAKAVI                            
License agreements                            
Revenues                 $ 66,200 $ 56,900 $ 122,600 $ 102,500    
Novartis | JAKAVI | Minimum                            
License agreements                            
Royalty payments on future global net sales (as a percent)                     12.00%      
Novartis | JAKAVI | Maximum                            
License agreements                            
Royalty payments on future global net sales (as a percent)                     14.00%      
Novartis | JAKAVI | Regulatory Milestones | Europe                            
License agreements                            
Amount recognized and received for the achievement of a predefined milestone         $ 60,000